Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Maturitas ; 19(3): 225-37, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7799829

ABSTRACT

Four sequential combined oestrogen and progestogen regimens were compared in terms of bleeding pattern and relief of climacteric symptoms. Treatment was with either 2 mg 17 beta-oestradiol with 1 mg norethisterone acetate [E2 + NETA]; 2 mg oestradiol valerate with 75 micrograms levonorgestrel [E2V + LNG]; 2 mg oestradiol valerate with 10 mg medroxyprogesterone acetate [E2V + MPA]; or 1.5 mg 17 beta-oestradiol with 150 micrograms desogestrel [E2 + DG]. A placebo-controlled study lasting 12-24 months was completed by 143 healthy early postmenopausal women. Bleeding lengths were not substantially different; in all regimens the majority of women were bleeding for 3-6 days. Bleeding onset showed differences when related to the 11th day of progestogen addition; in the regimen with E2V + LNG, 21% of the women women were bleeding before the 11th day of progestogen addition 26% on, and 53% after that day. In the regimen with E2V + MPA, 56% of the women were bleeding before the 11th day, 28% on, and 17% after that day, whereas in the regimen with E2 + DG, 15% of the women were bleeding before the 11th day, 5% on, and 80% after that day. All regimens reduced climacteric symptoms to the same extent. Breast tenderness occurred in all the regimens, except in the E2 + DG. Conclusively, the differences between the responses to treatment were not conspicuous. However, our data indicate that one regimen (E2 + DG) resulted in optimal bleeding control, optimal effect on climacteric symptoms, and no production of breast tenderness.


Subject(s)
Climacteric/drug effects , Estrogen Replacement Therapy , Progesterone Congeners/therapeutic use , Breast/drug effects , Desogestrel/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Estradiol/analogs & derivatives , Estradiol/therapeutic use , Estrogens, Conjugated (USP)/therapeutic use , Female , Flushing/prevention & control , Humans , Levonorgestrel/therapeutic use , Medroxyprogesterone Acetate/therapeutic use , Menstrual Cycle/drug effects , Middle Aged , Norethindrone/analogs & derivatives , Norethindrone/therapeutic use , Norethindrone Acetate , Progesterone Congeners/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...